Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07024693 | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | PHASE2 | RECRUITING | 28 | — | — | Jul 30, 2025 | Dec 1, 2026 | Dec 29, 2025 | 2 | United States |
Assessment of DT-168 on splicing patterns in genes that are known to be disrupted in FECD.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Drug: DT-168 |
| Name | Type | Description |
|---|---|---|
| DT-168 | DRUG | Active |
Inclusion Criteria: * Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study. * ≥30 years of age (inclusive). * Documented diagnosis of FECD in the study eligible eye. * Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele. * Ca...